| Revenue growth | 12% Q-o-Q revenue growth delivered in Q4 FY26. |
|---|---|
| Margins | Base business at 54% gross margin; overall EBITDA margin 16%. |
| Order book | Base business order book remains strong and a primary driver. |
| Demand visibility | Healthy order book in base business; 30% spare capacity available. |
| Management confidence | High in base business; cautious on Ibuprofen turnaround. |
Growth
Revenue grew 12% Q-o-Q; EBITDA grew 65% Q-o-Q to INR 61cr; 16% overall EBITDA margin.
Outlook
Evaluating strategic options for Ibuprofen; aiming to be debt-free by FY29; 4-5 DMF filings planned annually.
Risks
Persistent headwinds in Ibuprofen (negative EBITDA); Middle East crisis impact; reliance on third-party IBB/IBAP sourcing.
Earnings Call filed with BSE, NSE: SOLARA. Summary written with AI assistance from the document.
Solara Active Pharma Sciences Ltd: key numbers
- Share price
- ₹739.15
- Market cap
- ₹3,552 Cr
- Revenue (annual)
- ₹1,369 Cr
- Net profit (annual)
- ₹-7.41 Cr
- P/E (TTM)
- -2192.7×Sector 50.4×
- Promoter holding
- 41.93%-0.07% QoQ
- FII holding
- 11.52%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Solara Active Pharma Sciences Ltd
All →Solara Active Pharma Sciences Other Announcement
Solara Active Pharma Sciences is notifying physical shareholders to update their PAN, KYC, and nomination details per SEBI circulars. This is a routine regulatory compliance intimation.
Solara Active Pharma Sciences Annual General Meeting
Solara Active Pharma Sciences Limited held its Ninth Annual General Meeting on September 18, 2026. Shareholders transacted business, including approving related party transactions.
Solara Active Pharma Sciences Earnings Call Transcript: Key Takeaways
Solara achieved record EBITDA/PAT despite significant geopolitical headwinds in West Asia impacting raw material costs.
- Call
- Guides 10% growth
Solara Active Pharma Sciences Q1 FY27 Results: Net Profit ₹16.3 Cr, Up 55.2% YoY
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹381.6 Cr (+19.6% YoY) and net profit of ₹16.3 Cr (+55.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹16.3 Cr · +55.2% YoY
Solara Active Pharma Sciences Earnings Call: Key Takeaways
Solara's base business shows strong momentum, hitting eight-quarter highs in revenue and EBITDA, yet the Ibuprofen segment remains a significant drag, forcing a strategic review and potential divestment of the vertical.
Solara Active Pharma Sciences Q4 FY26 Results: Turns Profitable, Net Profit ₹9.6 Cr
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹387.3 Cr (+41.9% YoY) and net profit of ₹9.6 Cr for Q4 FY26.
- Key figure
- Net profit ₹9.6 Cr